News

Dundalk, Ireland, October 19, 2022 — WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), announced the mechanical completion of its vaccine manufacturing facility in Dundalk, Ireland.

The Dundalk site is a greenfield development of an integrated vaccine manufacturing facility to be used as part of a 20-year, USD3 billion vaccine manufacturing contract with a global pharmaceutical company. The site is designed to carry out multiple functions including Drug Substance (DS), Drug Product (DP), Manufacturing Science and Technology Labs (MS&T), as well as Quality Control (QC) labs.

Despite the disruptive impact of the COVID-19 pandemic, the facility reached its mechanical completion within 30 months of ground-breaking in June, 2020, the result of 3 million person-hours to date and with exemplary safety and quality performance.

Mr. Jian Dong, CEO of WuXi Vaccines, said, “I’m thrilled to celebrate the mechanical completion with our staff, the strategic partner and project agents here in Dundalk, Ireland. The Irish tradition is a fusion of people’s belief, hope and imagination, all of which motivated us to overcome various challenges to deliver this facility. Achieving mechanical completion is a critical milestone, and it laid out a solid foundation for the next steps of commissioning, qualification and validation (CQV), tech transfer (TT), and process performance qualification (PPQ), ultimately leading towards the launch of a great innovative vaccine. With the tremendous efforts of our ‘One Team with One Goal’, we conquered many challenges during the pandemic. I foresee continued success in launching this product to help benefit people worldwide.”

About WuXi Vaccines

WuXi Vaccines focuses on human vaccine discovery, development and manufacturing. As an industry-leading CDMO, it provides world-class integrated development and manufacturing platforms to expedite partners’ vaccines to clinical stage and the market. Regardless of the vaccine modality (i.e., protein, virus, VLP, DNA, mRNA/RNA), WuXi Vaccines leverages its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (mammalian, microbial), and extensive GMP manufacturing capacities to provide an end-to-end service – from vaccine discovery and development to large-scale commercial production and distribution. The company can

enable any global partner to deliver critical vaccines anywhere in the world.

For more information, please visit wuxivaccines.com